title: Treatment with cytotoxic immunosuppression agents increases urinary excretion of JCV in patients with autoimmune disease.
abstract: Human JC virus is ubiquitous in human populations and is reactivated frequently in immunosuppressed patients. Fifty-one patients with autoimmune disease receiving immunomodulating therapy were evaluated to study the possible relationship between immunosuppression and JCV viruria. Patients were divided into cytotoxic and noncytotoxic treatment groups based on their prescription. The incidence of JCV viruria in the cytotoxic treatment group was significantly higher than that in the noncytotoxic group (67% vs. 28%; P < 0.05). Most patients with JCV viruria were receiving corticosteroid (P = 0.03 for any dose and P < 0.001 for higher-dose treatments) and cytotoxic agents (P = 0.02). Age, disease duration, and medication duration appeared not to be the precipitating factors of JCV viruria in this study. The results of clinical evaluation indicate that cytotoxic immunosuppression may play an important role in JC virus reactivation.
authors.affiliation: Department of Microbiology and Immunology, Chung Shan Medical and Dental College, Taichung, Taiwan, Republic of China.
authors.forename: M
authors.initials: M
authors.lastname: Wang
authors.forename: R T
authors.initials: RT
authors.lastname: Tsai
authors.forename: W C
authors.initials: WC
authors.lastname: Ou
authors.forename: C K
authors.initials: CK
authors.lastname: Lin
authors.forename: G J
authors.initials: GJ
authors.lastname: Tsay
authors.forename: H
authors.initials: H
authors.lastname: Chang
authors.forename: D
authors.initials: D
authors.lastname: Chang
mesh_terms: D000293:Adolescent; D000305:Adrenal Cortex Hormones; D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy / Q000652:urine / Q000821:virology; D001327:Autoimmune Diseases / Q000150:complications / Q000188:drug therapy* / Q000652:urine / Q000821:virology*; D003603:Cytotoxins / Q000627:therapeutic use*; D004279:DNA, Viral / Q000652:urine; D003882:Dermatomyositis / Q000150:complications / Q000188:drug therapy / Q000652:urine / Q000821:virology; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015994:Incidence; D007577:JC Virus / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification*; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000188:drug therapy / Q000652:urine / Q000821:virology; D008297:Male; D008875:Middle Aged; D030361:Papillomavirus Infections / Q000150:complications / Q000652:urine / Q000821:virology*; D012859:Sjogren's Syndrome / Q000150:complications / Q000188:drug therapy / Q000652:urine / Q000821:virology; D014412:Tumor Virus Infections / Q000150:complications / Q000652:urine / Q000821:virology*
chemical_list: D000305:Adrenal Cortex Hormones; D003603:Cytotoxins; D004279:DNA, Viral; D007166:Immunosuppressive Agents